FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma

Status Withdrawn

Clinical Trial Summary

This is a Phase I study of FT596 in combination with two different schedules (standard or alternate) of R-CHOP in subjects with B-cell lymphoma who are previously untreated or have received no more than one prior line of treatment. The study will consist of a dose-escalation stage followed by a dose-expansion stage.

Clinical Trial Description

This is a Phase I study of FT596 in combination with 2 different schedules (standard or alternate) of R-CHOP in subjects with B-cell lymphoma who are previously untreated or have received no more than one prior line of treatment. The study will evaluate both the clinical benefit of FT596 when combined with R-CHOP given on a standard or alternate schedule. Subjects will be enrolled in two stages: a dose-escalation stage and a dose-expansion stage. After safety and tolerability have been assessed to define the maximum tolerated dose (MTD) (or the maximum assessed dose [MAD] in the absence of dose limiting toxicities [DLTs] defining the MTD) in the dose-escalation stage, the dose-expansion stage will further evaluate the safety and activity of FT596 in combination. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05934097
Study type	Interventional
Source	Fate Therapeutics
Contact
Status	Withdrawn
Phase	Phase 1
Start date	December 2022
Completion date	May 2039

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT01804686` - A Long-term Extension Study of PCI-32765 (Ibrutinib)	Phase 3
Recruiting	`NCT05976763` - Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma	Phase 3
Recruiting	`NCT03676504` - Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR	Phase 1/Phase 2
Recruiting	`NCT05365659` - IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas	Phase 1
Recruiting	`NCT05471843` - Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma	Phase 1/Phase 2
Recruiting	`NCT05076097` - A Study of OLR in First-line Treatment of Mantle Cell Lymphoma	Phase 2
Active, not recruiting	`NCT03891355` - Carfilzomib + Lenalidomide and Dexamethasone for BTK Inhibitors Relapsed-refractory or Intolerant MCL	Phase 2
Active, not recruiting	`NCT04082936` - A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma	Phase 1/Phase 2
Recruiting	`NCT04883437` - Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas	Phase 2
Terminated	`NCT03585725` - A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma	Early Phase 1
Recruiting	`NCT02892695` - PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma	Phase 1/Phase 2
Terminated	`NCT02877082` - Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients	Phase 2
Completed	`NCT01665768` - Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma	Phase 2
Completed	`NCT01437709` - Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant	Phase 2
Completed	`NCT00963534` - Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.	Phase 1/Phase 2
Completed	`NCT00921414` - Mantel Cell Lymphoma Efficacy of Rituximab Maintenance	Phase 3
Withdrawn	`NCT00541424` - Combined CT Colonography and PET Imaging in Mantle Cell Lymphoma	N/A
Completed	`NCT01456351` - Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab	Phase 3
Completed	`NCT01851551` - Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL	Phase 1/Phase 2
Completed	`NCT03295240` - The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma	Early Phase 1